Baginska, Joanna
Nau, Allison
Gomez Diaz, Ilana
Giobbie-Hurder, Anita
Weirather, Jason
Vergara, Juliana
Abrecht, Charlotte
Hallisey, Margaret
Dennis, Jenna
Severgnini, Mariano
Huezo, Julia
Marciello, Isabella
Rahma, Osama
Manos, Michael
Brohl, Andrew S.
Bedard, Philippe L.
Renouf, Daniel J.
Sharon, Elad
Streicher, Howard
Ott, Patrick A.
Buchbinder, Elizabeth I.
Hodi, F. Stephen
Funding for this research was provided by:
National Cancer Institute
Merck, Sharpe, and Dohme
Sanofi
Article History
Received: 7 November 2023
Accepted: 11 December 2023
First Online: 18 January 2024
Declarations
:
: Joanna Baginska—no relevant disclosures, Allison Nau—no relevant disclosures, Ilana Gomez Diaz—no relevant disclosures, Anita Giobbie-Hurder—no relevant disclosures, Jason Weirather—no relevant disclosures, Juliana Vergara—no relevant disclosures, Charlotte Abrecht—no relevant disclosures, Margaret Hallisey—no relevant disclosures, Jenna Dennis—no relevant disclosures, Mariano Severgnini—no relevant disclosures, Julia Huezo—no relevant disclosures, Isabella Marciello—no relevant disclosures. Osama Rahma—OER is supported with research funding from Merck; received consulting fees from Merck, Celgene, Five Prime, GSK, Bayer, Roche/Genentech, Puretech, Imvax, Sobi, and Boehringer Ingelheim, all unrelated to this work. Pending patent for “Methods of using pembrolizumab and trebananib.” OER also reports employment with AstraZeneca (not at the time of conducting this work). Michael Manos—no relevant disclosures, Andrew S Brohl—Advisory Board: Deciphera and Bayer, Philippe L Bedard—Research funding (to institution) from Amgen, Astra Zeneca, Bayer, Bicara, BristolMyersSquibb, Genentech/Roche, GlaxoSmithKline, Lilly, Merck, Nektar, Novartis, PTC Therapeutics, Sanofi, SeaGen, Servier, SignalChem Life Sciences, and Zymeworks; uncompensated advisory for Zymeworks, Lilly, SeaGen, Merck, Amgen, Gilead, and Repare Therapeutics. Daniel J Renouf—no relevant disclosures, Elad Sharon—no relevant disclosures, Howard Streicher—no relevant disclosures, Patrick A Ott—Advisory Role: Alexion, Array, Bristol-Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, TRM Oncology, Evaxion, Immunetune, Servier, MyNeo, and Phio; Grants to institution: Armo Biosciences, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, and Pfizer. Elizabeth I Buchbinder—Consulting as an advisory board member for Merck, Iovance, Sanofi, Xilio, Novartis, Instilbio, and Nektar. Clinical trial support from Lilly, Novartis, Partners therapeutics, Genentech, and BVD. F. Stephen Hodi—grants and personal fees from Bristol-Myers Squibb, personal fees from Merck, grants and personal fees from Novartis, personal fees from Surface, personal fees from Compass Therapeutics, personal fees from Apricity, personal fees from Bicara, personal fees from Checkpoint Therapeutics, personal fees from Genentech/Roche, personal fees from Bioentre, personal fees from Gossamer, personal fees from Iovance, personal fees from Catalym, personal fees from Immunocore, personal fees from Kairos, personal fees from Rheos, personal fees from Zumutor, personal fees from Corner Therapeuitcs, personal fees from Puretech, personal fees from Curis, and personal fees from Astra Zeneca, outside the submitted work. In addition, Dr. Hodi has a patent Methods for Treating MICA-Related Disorders (#20100111973) with royalties paid, a patent tumor antigens and uses thereof (#7250291) issued, a patent Angiopoiten-2 Biomarkers Predictive of Anti-immune checkpoint response (#20170248603) pending, a patent Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (#20160340407) pending, a patent Therapeutic peptides (#20160046716) pending, a patent Therapeutic Peptides (#20140004112) pending, a patent Therapeutic Peptides (#20170022275) pending, a patent Therapeutic Peptides (#20170008962) pending, a patent THERAPEUTIC PEPTIDES Therapeutic Peptides Patent number: 9402905 issued, a patent METHODS OF USING PEMBROLIZUMAB AND TREBANANIB pending, a patent Vaccine compositions and methods for restoring NKG2D pathway function against cancers Patent number: 10279021 issued, a patent Antibodies that bind to MHC class I polypeptide-related sequence A Patent number: 10106611 issued, and a patent ANTI-GALECTIN ANTIBODY BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT AND ANTI-ANGIOGENESIS RESPONSES.
: This study involves human participants and was approved for clinical trial by institutional review boards at all sites. Participants provided written informed consent to participate in the study before taking part. This study involves human participants and the ethics committee at each investigational site approved the protocol. Participants gave informed consent to participate in the study before taking part.
: Not applicable.